The Tata Institute in Mumbai has unveiled a revolutionary advancement in cancer treatment. Following an intensive ten-year research endeavor, they have introduced a tablet designed to impede cancer recurrence and alleviate treatment side effects by 50%.
The ‘R+Cu’ tablet, pioneered by researchers and medical experts at the Tata Institute, incorporates pro-oxidant compounds such as resveratrol and copper. These elements produce oxygen radicals within the stomach, effectively dismantling chromatin particles discharged by deteriorating cancer cells. This process not only stymies healthy cell transformation into cancerous ones but also curtails cancer cell migration, known as ‘Metastasis’.
Dr. Rajendra Badwe, a senior cancer surgeon at Tata Memorial Hospital, disclosed that the tablet underwent rigorous testing on rats to assess its preventive and side effect mitigation properties, yielding promising outcomes. Nonetheless, human trials remain ongoing and are anticipated to span approximately five years. Regulatory approval from the Food Safety and Standards Authority of India (FSSAI) is pending, with expectations for the tablet to hit the market by June-July.
An integral aspect of this breakthrough is its affordability. While cancer treatments often incur costs ranging from lakhs to crores, the projected price of this tablet stands at a mere ₹100, rendering it accessible to a broader demographic.
Dr. Badve emphasized the extensive efforts invested by Tata doctors over nearly a decade in developing this tablet, expressing optimism about its potential impact on cancer treatment. Pending FSSAI approval, the tablet is poised to enter the market, promising significant enhancements in cancer care.
Looking ahead, the tablet not only exhibits promise in averting cancer recurrence but also in mitigating treatment side effects. Researchers foresee its efficacy in addressing various cancers including pancreatic, lung, and oral malignancies.
The advent of this tablet heralds a monumental breakthrough in cancer therapy, instilling hope among patients and potentially reshaping the landscape of oncological care. Its combination of affordability and effectiveness positions it as a transformative force in oncology.
Source of this information: NDTV interview with Dr. Rajendra Achyut Badwe, Director of Tata Memorial Center.